Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Neovacs raises €10 million In First French Biotech IPO In Two Years

This article was originally published in The Pink Sheet Daily

Executive Summary

Neovacs floats on the Alternext beginning April 21, following tough year for the country's biotech sector.

You may also be interested in...



Neovacs Advances Anti-TNF Immunotherapy In Crohn's Patients Who Failed Biologics

Completed Phase I/II trial offered the first indication of clinical benefit with an active immunotherapy against a cytokine, the French biotech's CEO says.

Neovacs Advances Anti-TNF Immunotherapy In Crohn's Patients Who Failed Biologics

Completed Phase I/II trial offered the first indication of clinical benefit with an active immunotherapy against a cytokine, the French biotech's CEO says.

Alimera Raises $72 Million In IPO; Clips Share Price To $11 From Initial $15-$17 Range

$15 million will be used to pay debt to Australian drug maker pSivida, which gave Alimera its lead compound.

Topics

UsernamePublicRestriction

Register

PS070498

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel